Cargando…

Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Aβ(42 )reduces their differentiation potential

BACKGROUND: Alzheimer's disease (AD) is characterized by neurodegeneration and changes in cellular processes, including neurogenesis. Proteolytic processing of the amyloid precursor protein (APP) plays a central role in AD. Owing to varying APP processing, several β-amyloid peptides (Aβ) are ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Uhrig, Markus, Brechlin, Peter, Jahn, Olaf, Knyazev, Yuri, Weninger, Annette, Busia, Laura, Honarnejad, Kamran, Otto, Markus, Hartmann, Tobias
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645429/
https://www.ncbi.nlm.nih.gov/pubmed/19087254
http://dx.doi.org/10.1186/1741-7015-6-38
_version_ 1782164787344441344
author Uhrig, Markus
Brechlin, Peter
Jahn, Olaf
Knyazev, Yuri
Weninger, Annette
Busia, Laura
Honarnejad, Kamran
Otto, Markus
Hartmann, Tobias
author_facet Uhrig, Markus
Brechlin, Peter
Jahn, Olaf
Knyazev, Yuri
Weninger, Annette
Busia, Laura
Honarnejad, Kamran
Otto, Markus
Hartmann, Tobias
author_sort Uhrig, Markus
collection PubMed
description BACKGROUND: Alzheimer's disease (AD) is characterized by neurodegeneration and changes in cellular processes, including neurogenesis. Proteolytic processing of the amyloid precursor protein (APP) plays a central role in AD. Owing to varying APP processing, several β-amyloid peptides (Aβ) are generated. In contrast to the form with 40 amino acids (Aβ(40)), the variant with 42 amino acids (Aβ(42)) is thought to be the pathogenic form triggering the pathological cascade in AD. While total-Aβ effects have been studied extensively, little is known about specific genome-wide effects triggered by Aβ(42 )or Aβ(40 )derived from their direct precursor C99. METHODS: A combined transcriptomics/proteomics analysis was performed to measure the effects of intracellularly generated Aβ peptides in human neuroblastoma cells. Data was validated by real-time polymerase chain reaction (real-time PCR) and a functional validation was carried out using RNA interference. RESULTS: Here we studied the transcriptomic and proteomic responses to increased or decreased Aβ(42 )and Aβ(40 )levels generated in human neuroblastoma cells. Genome-wide expression profiles (Affymetrix) and proteomic approaches were combined to analyze the cellular response to the changed Aβ(42)- and Aβ(40)-levels. The cells responded to this challenge with significant changes in their expression pattern. We identified several dysregulated genes and proteins, but only the cellular retinoic acid binding protein 1 (CRABP1) was up-regulated exclusively in cells expressing an increased Aβ(42)/Aβ(40 )ratio. This consequently reduced all-trans retinoic acid (RA)-induced differentiation, validated by CRABP1 knock down, which led to recovery of the cellular response to RA treatment and cellular sprouting under physiological RA concentrations. Importantly, this effect was specific to the AD typical increase in the Aβ(42)/Aβ(40 )ratio, whereas a decreased ratio did not result in up-regulation of CRABP1. CONCLUSION: We conclude that increasing the Aβ(42)/Aβ(40 )ratio up-regulates CRABP1, which in turn reduces the differentiation potential of the human neuroblastoma cell line SH-SY5Y, but increases cell proliferation. This work might contribute to the better understanding of AD neurogenesis, currently a controversial topic.
format Text
id pubmed-2645429
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26454292009-02-20 Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Aβ(42 )reduces their differentiation potential Uhrig, Markus Brechlin, Peter Jahn, Olaf Knyazev, Yuri Weninger, Annette Busia, Laura Honarnejad, Kamran Otto, Markus Hartmann, Tobias BMC Med Research Article BACKGROUND: Alzheimer's disease (AD) is characterized by neurodegeneration and changes in cellular processes, including neurogenesis. Proteolytic processing of the amyloid precursor protein (APP) plays a central role in AD. Owing to varying APP processing, several β-amyloid peptides (Aβ) are generated. In contrast to the form with 40 amino acids (Aβ(40)), the variant with 42 amino acids (Aβ(42)) is thought to be the pathogenic form triggering the pathological cascade in AD. While total-Aβ effects have been studied extensively, little is known about specific genome-wide effects triggered by Aβ(42 )or Aβ(40 )derived from their direct precursor C99. METHODS: A combined transcriptomics/proteomics analysis was performed to measure the effects of intracellularly generated Aβ peptides in human neuroblastoma cells. Data was validated by real-time polymerase chain reaction (real-time PCR) and a functional validation was carried out using RNA interference. RESULTS: Here we studied the transcriptomic and proteomic responses to increased or decreased Aβ(42 )and Aβ(40 )levels generated in human neuroblastoma cells. Genome-wide expression profiles (Affymetrix) and proteomic approaches were combined to analyze the cellular response to the changed Aβ(42)- and Aβ(40)-levels. The cells responded to this challenge with significant changes in their expression pattern. We identified several dysregulated genes and proteins, but only the cellular retinoic acid binding protein 1 (CRABP1) was up-regulated exclusively in cells expressing an increased Aβ(42)/Aβ(40 )ratio. This consequently reduced all-trans retinoic acid (RA)-induced differentiation, validated by CRABP1 knock down, which led to recovery of the cellular response to RA treatment and cellular sprouting under physiological RA concentrations. Importantly, this effect was specific to the AD typical increase in the Aβ(42)/Aβ(40 )ratio, whereas a decreased ratio did not result in up-regulation of CRABP1. CONCLUSION: We conclude that increasing the Aβ(42)/Aβ(40 )ratio up-regulates CRABP1, which in turn reduces the differentiation potential of the human neuroblastoma cell line SH-SY5Y, but increases cell proliferation. This work might contribute to the better understanding of AD neurogenesis, currently a controversial topic. BioMed Central 2008-12-16 /pmc/articles/PMC2645429/ /pubmed/19087254 http://dx.doi.org/10.1186/1741-7015-6-38 Text en Copyright © 2008 Uhrig et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Uhrig, Markus
Brechlin, Peter
Jahn, Olaf
Knyazev, Yuri
Weninger, Annette
Busia, Laura
Honarnejad, Kamran
Otto, Markus
Hartmann, Tobias
Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Aβ(42 )reduces their differentiation potential
title Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Aβ(42 )reduces their differentiation potential
title_full Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Aβ(42 )reduces their differentiation potential
title_fullStr Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Aβ(42 )reduces their differentiation potential
title_full_unstemmed Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Aβ(42 )reduces their differentiation potential
title_short Upregulation of CRABP1 in human neuroblastoma cells overproducing the Alzheimer-typical Aβ(42 )reduces their differentiation potential
title_sort upregulation of crabp1 in human neuroblastoma cells overproducing the alzheimer-typical aβ(42 )reduces their differentiation potential
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2645429/
https://www.ncbi.nlm.nih.gov/pubmed/19087254
http://dx.doi.org/10.1186/1741-7015-6-38
work_keys_str_mv AT uhrigmarkus upregulationofcrabp1inhumanneuroblastomacellsoverproducingthealzheimertypicalab42reducestheirdifferentiationpotential
AT brechlinpeter upregulationofcrabp1inhumanneuroblastomacellsoverproducingthealzheimertypicalab42reducestheirdifferentiationpotential
AT jahnolaf upregulationofcrabp1inhumanneuroblastomacellsoverproducingthealzheimertypicalab42reducestheirdifferentiationpotential
AT knyazevyuri upregulationofcrabp1inhumanneuroblastomacellsoverproducingthealzheimertypicalab42reducestheirdifferentiationpotential
AT weningerannette upregulationofcrabp1inhumanneuroblastomacellsoverproducingthealzheimertypicalab42reducestheirdifferentiationpotential
AT busialaura upregulationofcrabp1inhumanneuroblastomacellsoverproducingthealzheimertypicalab42reducestheirdifferentiationpotential
AT honarnejadkamran upregulationofcrabp1inhumanneuroblastomacellsoverproducingthealzheimertypicalab42reducestheirdifferentiationpotential
AT ottomarkus upregulationofcrabp1inhumanneuroblastomacellsoverproducingthealzheimertypicalab42reducestheirdifferentiationpotential
AT hartmanntobias upregulationofcrabp1inhumanneuroblastomacellsoverproducingthealzheimertypicalab42reducestheirdifferentiationpotential